NCT05824091View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

March 26, 2024

Study Completion Date

March 26, 2024

Conditions
Tuberculosis
Interventions
DRUG

MK-7762 (TBD09)

Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD

OTHER

Placebo

A subset of participants from each of the 6 dosing cohorts will receive placebo.

Trial Locations (1)

68502

Investigational Site, Lincoln

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Gates Medical Research Institute

OTHER